J.C. Hassel

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

Georgina V. Long, Victoria Atkinson, Paolo A. Ascierto et al. · Annals of Oncology · 2016 · 118 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

A Phase 3 Randomized, Open-Label Study of Nivolumab (Anti-Pd-1; Bms-936558; Ono-4538) Versus Investigator'S Choice Chemotherapy (Icc) in Patients with Advanced Melanoma After Prior Anti-Ctla-4 Therapy

Jeffrey S. Weber, David R. Minor, Sandra P. D’Angelo et al. · Annals of Oncology · 2014 · 71 citations · Full text

Medicine, Immunology, Oncology +14

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome

J.C. Hassel, Antje Sucker, Lutz Edler et al. · British Journal of Cancer · 2010 · 43 citations · Full text

Medicine, Genetics, Oncology +17

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

James Larkin, Vanna Chiarion‐Sileni, R. Gonzalez et al. · European Journal of Cancer · 2015 · 37 citations

Life Sciences, Immunology, Oncology +13

PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis

Georgina V. Long, James Larkin, Paolo A. Ascierto et al. · Annals of Oncology · 2016 · 26 citations · Full text

Medicine, Immunology, Oncology +16